AP
DGX icon

Antipodes Partners’s Quest Diagnostics DGX Stock Holding History

Antipodes Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
77,785
-84,804
-52% -$16.6M 0.3% 61
2026
Q1 		$31.9M Sell
162,589
-9,398
-5% -$1.83M 0.61% 45
2025
Q4 		$29.8M Buy
171,987
+110,280
+179% +$20.1M 0.63% 47
2025
Q3 		$11.8M Buy
61,707
+60,707
+6,071% +$10.8M 0.26% 54
2025
Q2 		$180K Buy
1,000
+198
+25% +$34.4K 0.01% 65
2025
Q1 		$136K Buy
+802
New +$132K ﹤0.01% 63

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Antipodes Partners's DGX Position: Q2 2026 in Review

Antipodes Partners reduced its Quest Diagnostics (DGX) stake by 52% in Q2 2026, selling an estimated $16.6M and leaving 77,785 shares worth $16.5M. The position accounts for 0.3% of the portfolio, ranked #61.

Antipodes Partners first reported a position in DGX in Q1 2025 and has held it in 6 quarters since. The position peaked at $31.9M in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Antipodes Partners held 77,785 shares of Quest Diagnostics worth $16.5M as of Q2 2026.
  • Antipodes Partners sold 84,804 Quest Diagnostics shares in Q2 2026, an estimated $16.6M.
  • Quest Diagnostics made up 0.3% of Antipodes Partners's portfolio in Q2 2026, its #61 holding.
  • Antipodes Partners first reported a position in Quest Diagnostics in Q1 2025 and has held it in 6 quarters since.
  • Antipodes Partners's Quest Diagnostics position peaked at $31.9M in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.